Option Care Health (OPCH) Draws Fresh Home Care Attention, Is It Still 20% Undervalued?
Option Care Health (OPCH) is gaining attention due to its home and alternate site infusion business, which could benefit from the shift of complex treatments to lower-cost home settings. While its share price has rebounded 8.41% over 90 days, it's down 29.25% year-to-date. Analysts believe it's 20.2% undervalued with a fair value of $28.58, driven by growth in infusion therapies and partnerships, but a discounted cash flow model suggests it might be overvalued at $22.81, estimating its future cash flow value at $18.15.
Option Care Health, Inc. (OPCH) Stock forecasts
Argus has raised its target price for Option Care Health, Inc. (OPCH) to $23.00. Option Care Health is a provider of home and alternate-site infusion services, offering treatments for various conditions including bleeding disorders, neurological disorders, and chronic inflammatory disorders. The report also lists the current price of OPCH at $23.07.
3 Healthcare Stocks with Warning Signs
This article identifies three healthcare stocks—Option Care Health (OPCH), Illumina (ILMN), and Merck (MRK)—that StockStory advises investors to approach with caution despite the healthcare industry's recent strong performance. The warnings are based on issues such as slowing sales growth, stagnant free cash flow, negative returns on capital, underwhelming revenue performance, and increasing expenses relative to revenue for these companies. The article suggests readers review detailed reports for a full understanding of these concerns.
Technical Reactions to OPCH Trends in Macro Strategies
This article from Stock Traders Daily discusses technical reactions to Option Care Health Inc. (NASDAQ: OPCH) trends, highlighting a stable neutral reading in shorter horizons that could indicate an easing of a long-term weak bias. It details three AI-generated institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored for different risk profiles, along with a multi-timeframe signal analysis. The analysis also points to an exceptional 73.3:1 risk-reward setup targeting a significant gain with minimal risk.
UBS reiterates Buy on Option Care Health stock on execution focus
UBS has reiterated a Buy rating and a $39.00 price target for Option Care Health (NASDAQ:OPCH), noting the company's consistent execution focus, strong performance in acute, immunoglobulin, and neurology portfolios, and expansion in chronic inflammatory disease. Despite a recent downgrade from Deutsche Bank due to growth concerns, InvestingPro data suggests the stock is undervalued, reinforcing UBS's positive outlook as the company explores tuck-in M&A opportunities and benefits from new therapies.
Option Care Health, Inc. (OPCH) Stock Analysis: Strong Buy Ratings and a 17.63% Upside Potential
Option Care Health, Inc. (OPCH) is a significant player in home and alternate site infusion services with a market cap of $3.64 billion. The company, currently trading at $24.30, has a positive outlook from analysts, with an average target price of $28.58 indicating a 17.63% upside potential. Despite not paying dividends, its strong free cash flow and strategic focus on growing healthcare demands position it as an attractive investment for growth-oriented investors.
Squarepoint Ops LLC Raises Stock Holdings in Option Care Health, Inc. $OPCH
Squarepoint Ops LLC significantly increased its stake in Option Care Health (NASDAQ:OPCH) during the second quarter, adding 304,376 shares to own a total of 434,408 shares valued at $9.1 million. This increase comes as Option Care Health exceeded quarterly earnings expectations with $0.45 adjusted EPS and $1.44 billion in revenue. Despite mixed analyst sentiment and some downgrades, a significant portion of the stock remains owned by hedge funds and institutional investors.
Option Care Health, Inc. (NASDAQ:OPCH) Given Consensus Rating of "Hold" by Brokerages
Option Care Health, Inc. (NASDAQ:OPCH) has received a consensus "Hold" rating from fourteen brokerages, with an average 12-month price target of $29.92. The company recently surpassed quarterly earnings and revenue expectations, reporting $0.45 EPS and $1.44 billion in revenue. Institutional investors hold a significant 98.05% of the company's outstanding shares.
Paralel Advisors LLC Purchases New Stake in Option Care Health, Inc. $OPCH
Paralel Advisors LLC has acquired a new stake in Option Care Health, Inc. (NASDAQ:OPCH), purchasing 85,835 shares valued at approximately $1.8 million in the second quarter. This move is part of broader institutional investor activity, with 98.05% of the company's stock owned by institutional investors and hedge funds. Despite mixed analyst ratings, Option Care Health exceeded quarterly earnings expectations, reporting $0.45 EPS and $1.44 billion in revenue.
Raiffeisen Bank International AG Purchases 120,000 Shares of Option Care Health, Inc. $OPCH
Raiffeisen Bank International AG significantly increased its stake in Option Care Health, Inc. by purchasing an additional 120,000 shares, bringing their total ownership to 250,000 shares valued at approximately $5.33 million. This move comes as Option Care Health has shown strong earnings, beating analysts' expectations, while its stock trades below its 52-week high. Analysts currently have a consensus "Hold" rating for the company with an average price target of $29.92.
Option Care Health Market Sentiment
This article provides an overview of market sentiment for Option Care Health (OPCH), detailing analyst consensus, short interest, options flow, and insider activity. Key signals indicate a "Buy" consensus from analysts, a 11.2% short float, and a bullish options flow with a 0.22 Put/Call ratio. The piece also lists recent analyst actions with their ratings, price targets, and changes.
Senior Health, Home Health & Hospice Stocks Q2 Results: Benchmarking Option Care Health (NASDAQ:OPCH)
This article analyzes Q2 earnings for senior health, home health, and hospice stocks, highlighting Option Care Health (OPCH) and its peers. Option Care Health reported strong Q2 results with revenues up 1.9% year-on-year, exceeding expectations. The broader industry faces challenges from labor costs and regulatory uncertainty but is poised for growth due to an aging population and increasing demand for in-home care.
Option Care Health to Participate in Upcoming Investor Conferences
Option Care Health announced that its CEO, John Rademacher, and CFO, Meenal Sethna, will participate in two upcoming investor conferences: the Morgan Stanley 24th Annual Global Healthcare Conference and the Deutsche Bank 2026 Healthcare Summit. The company, which is the nation's largest independent provider of home and alternate site infusion services, will make webcast links and presentation materials available on its investor relations website.
Two New York healthcare conferences will include Option Care Health’s CEO and CFO.
Option Care Health (OPCH) announced that its CEO, John Rademacher, and CFO, Meenal Sethna, will participate in two upcoming healthcare investor conferences in New York City in mid-September 2026. The company will present at the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026, and the Deutsche Bank 2026 Healthcare Summit on September 16, 2026. Webcast links and presentation materials will be available on Option Care Health's investor relations website.
Bank of New York Mellon Corp Invests $19.60 Million in Option Care Health, Inc. $OPCH
Bank of New York Mellon Corp has acquired a new stake of 934,655 shares, valued at approximately $19.6 million, in Option Care Health, Inc. This investment represents about 0.62% of the company, with institutional investors now holding 98.05% of OPCH stock. Option Care Health recently surpassed quarterly earnings expectations, reporting $0.45 in adjusted EPS and $1.44 billion in revenue.
Wellington Management Group LLP Has $247.08 Million Holdings in Option Care Health, Inc. $OPCH
Wellington Management Group LLP decreased its stake in Option Care Health, Inc. by 1% in the second quarter but still retains a significant holding of 11.78 million shares valued at approximately $247.1 million, representing 7.87% of the company. Institutional ownership of Option Care Health is very high at 98.05%, with a mixed analyst sentiment leading to a consensus "Hold" rating and an average price target of $29.92. The company reported strong Q2 earnings, exceeding revenue and EPS estimates, with shares opening at $23.90, below their 52-week high.
Option Care Health, Inc. (OPCH) Stock Analysis: Navigating Growth with a 19% Upside Potential
Option Care Health, Inc. (OPCH) is a key player in home and alternate site infusion services, with a market capitalization of $3.59 billion and a potential upside of 19.37% based on an average price target of $28.58. The company shows operational efficiency with a robust return on equity of 16.00% and positive analyst sentiment, including eight buy ratings. Technical analysis suggests short-term bullish momentum, positioning OPCH to capitalize on the evolving home-based care sector.
Option Care Health (NASDAQ:OPCH): A Quality Stock with Durable Growth and Cash Flow
Option Care Health (NASDAQ:OPCH) is highlighted as a quality stock demonstrating durable growth and strong cash flow, passing a demanding "Caviar Cruise" screen. The company shows healthy revenue and EBIT growth, high return on invested capital, and robust profit quality with strong free cash flow generation. While financial health presents minor caveats, the stock trades at an attractive valuation for a quality-oriented strategy.
Option Care Health, Inc. (NASDAQ:OPCH) Given Average Rating of "Moderate Buy" by Brokerages
Option Care Health, Inc. (NASDAQ:OPCH) has received a consensus "Moderate Buy" rating from 14 analysts, with seven rating it a "buy" and seven a "hold." The average 12-month price target is $29.92, surpassing its current share price of $23.94, despite some recent analyst downgrades and price target cuts. The company reported strong quarterly earnings, exceeding EPS and revenue estimates, and institutional investors hold a significant majority of its shares.
Durable Capital discloses 6.16M Option Care shares in 13G/A filing (OPCH)
Durable Capital Partners has filed an amended ownership report for Option Care Health, Inc. common stock, revealing a 3.9% stake. Durable Capital Master Fund LP directly holds 6,163,722 shares, with Durable Capital Partners acting as the investment adviser having sole voting and dispositive power over these shares. This filing indicates that the economic benefits of these shares are distributed among related parties based on existing agreements.
Bank of America Corp DE Increases Stock Position in Option Care Health, Inc. $OPCH
Bank of America Corp DE significantly increased its stake in Option Care Health, Inc. (NASDAQ:OPCH) by 14.6% in the first quarter, now owning 1.24% of the company. This move comes as institutional investors continue to hold a high percentage of the stock and Option Care Health reported better-than-expected earnings and revenue. Analysts currently maintain a "Hold" rating for the company.
First Trust Advisors LP Reduces Holdings in Option Care Health, Inc. $OPCH
First Trust Advisors LP significantly reduced its stake in Option Care Health, Inc. (NASDAQ:OPCH) by 53% in the first quarter, selling 43,153 shares and retaining 38,226 shares valued at approximately $1.03 million. Despite this, institutional investors collectively hold a substantial 98.05% of the company's stock. Analyst sentiment is mixed, with a consensus "Hold" rating and an average price target of $29.92, while the company recently surpassed quarterly earnings and revenue expectations.
Option Care Health (OPCH) Beat Expectations, Is The Stock Fully Priced?
Option Care Health (OPCH) recently reported strong Q2 2026 results, exceeding revenue, EBITDA, and EPS expectations, while maintaining guidance and investing in digital tools and clinic expansion. Despite a 15.99% share price rebound over 90 days, the stock is down 26.21% year-to-date and 15.64% over one year, raising questions about its current valuation. While one narrative suggests OPCH is 16.8% undervalued with a fair value of $28.58 based on long-term cash flow and growth prospects, another DCF model indicates it might be overvalued at its current price of $23.79, valuing it at $18.25 per share.
5 Insightful Analyst Questions From Option Care Health’s Q2 Earnings Call
Option Care Health (OPCH) exceeded Wall Street's expectations in Q2 2026 due to strong organic growth in acute therapies, stabilization in chronic inflammatory disease portfolios, and effective cost control. The earnings call highlighted key analyst questions covering revenue mix impact on margins, the speed of commercial team realignments, drivers for the expected sequential ramp in the second half, potential Medicare expansion for home infusion, and the role of cost cuts in guidance. Management provided explanations that underscored the company's strategic focus on clinical care, technology investments, and productivity improvements for sustained growth.
BIOS5286972 Bond Profile — Key Metrics
This article provides key metrics for the Option Care Health, Inc. 4.375% 31-OCT-2029 bond (BIOS5286972), including its issuer details, issue and maturity dates, outstanding amount, face value, minimum denomination, and coupon rate. It also describes Option Care Health's business as a provider of home and alternate site infusion services.
OPCH|Option Care Health Inc|Price:23.665|Chg%:-0.035
This article provides a comprehensive stock analysis of Option Care Health Inc (OPCH) from TradingKey, highlighting its strong fundamentals, high growth potential, and "fairly valued" status within the Healthcare Providers & Services industry. It notes strong institutional ownership, recent "Buy" ratings from analysts with a target price of $28.18, and an expectation for the stock price to trend upward in the medium term, despite current technicals indicating sideways trading. The report also details the company's strengths, such as revenue growth, and risks like lower market activity and institutional selling.
Option Care Health (NASDAQ:OPCH) Upgraded to "Buy" at Wall Street Zen
Option Care Health (NASDAQ:OPCH) was upgraded to a "Buy" rating from "Hold" by Wall Street Zen. The company recently reported strong quarterly earnings, beating estimates with $1.44 billion in revenue and $0.45 EPS. Despite this upgrade, the broader analyst consensus remains a "Hold" with a target price of $29.92, although several analysts have adjusted their price targets.
Renaissance Technologies LLC Purchases 75,100 Shares of Option Care Health, Inc. $OPCH
Renaissance Technologies LLC increased its stake in Option Care Health (NASDAQ:OPCH) by 15.5%, acquiring an additional 75,100 shares, bringing its total to 558,926 shares valued at $15 million. Institutional investors now own 98.05% of the company, while insiders recently purchased 73,264 shares totaling about $1.55 million. Despite mixed analyst ratings, Option Care Health reported strong quarterly earnings of $0.45 per share and revenue of $1.44 billion, surpassing analyst estimates.
Bank of America Securities Keeps Their Hold Rating on Option Care Health (OPCH)
Bank of America Securities analyst Joanna Gajuk reiterated a Hold rating on Option Care Health (OPCH) with a price target of $25.00, following the company's recent earnings report. Option Care Health reported quarterly revenue of $1.44 billion and a net profit of $53.91 million for the quarter ending June 30. Despite a Hold rating from Deutsche Bank as well, William Blair maintained a Buy rating, and insider sentiment on the stock is positive, with increased insider buying over the past quarter.
Option Care Health earnings up next as census recovery takes center stage
Option Care Health (OPCH) is set to report its second-quarter results, with investor attention focused on patient census recovery amidst biosimilar drug headwinds and competitive pressures. Analysts expect improved sequential earnings and revenue, but year-over-year revenue growth is anticipated to be flat, leading to reduced outlooks. The company's ability to demonstrate patient growth and cost discipline will be key to restoring investor confidence, especially after a prior revenue miss and cautious guidance.
Option Care Health Inc Earnings Call Shows Cautious Momentum
Option Care Health Inc. (OPCH) reported its Q2 2026 earnings, showcasing cautious momentum with solid sequential revenue and EBITDA gains, strong cash generation, and an active share repurchase program. Despite these positives, the company faces headwinds in its chronic inflammatory disease portfolio, which is expected to temper overall growth and gross profit for 2026. Management reaffirmed its full-year guidance, anticipating steady progress in the second half through strategic investments and initiatives.
Option Care Health's Q2 Adjusted Earnings, Revenue Rise
Option Care Health (OPCH) reported an increase in its Q2 adjusted earnings, reaching $0.45 per diluted share. Revenue also rose during the quarter. The full details of the article require a premium subscription.
Barrington Maintains Option Care Health(OPCH.US) With Buy Rating, Raises Target Price to $33
Barrington has reiterated its "Buy" rating for Option Care Health (OPCH.US) and increased its price target to $33. This indicates a positive outlook from the analyst firm regarding the company's future performance and stock value.
Option Care Health (OPCH) Could Be 27% Undervalued After Q2 Results And Guidance
Option Care Health (OPCH) recently released strong Q2 2026 results and updated guidance, leading to a 7.06% 30-day stock price return. Despite a year-to-date decline of 30.37%, the company is considered undervalued by some analyses, with a fair value estimate of $28.58 against a last close of $22.45. This undervaluation is attributed to growth in infusion therapies and strategic partnerships, although a discounted cash flow model suggests a more cautious valuation of $18.46.
Deutsche Bank Downgrades Option Care Health to Hold From Buy, Adjusts PT to $24 From $26
Deutsche Bank has downgraded Option Care Health (OPCH) from a "Buy" rating to "Hold" and reduced its price target from $26 to $24. This action indicates a revised outlook on the stock's performance. Previously, Stephens also downgraded Option Care to "Equal Weight" from "Overweight" with a price target of $24.
Deutsche Bank cuts Option Care Health stock rating on growth concerns
Deutsche Bank downgraded Option Care Health (NASDAQ:OPCH) from Buy to Hold, lowering its price target to $24.00 from $26.00 due to concerns about the company's long-term growth prospects. Despite an EBITDA beat, the firm noted challenges in maintaining acute growth significantly above market and questioned the sustainability of gross profit growth without reliance on SG&A cost cutting. This contrasts with InvestingPro's analysis, which suggests the stock is undervalued, while recent Q2 earnings exceeded expectations.
Option Care: Q2 Earnings Snapshot
This article provides a brief earnings snapshot for Option Care's Q2 performance. As a content cleaning and metadata extraction exercise, the article itself contains no financial details or specific figures beyond its title. It's an example of an article placeholder or a very short, uninformative release.
Option Care Health Q2 Earnings Call Highlights
Option Care Health reported strong second-quarter 2026 results, exceeding internal expectations with sequential improvements in revenue, adjusted EBITDA, and adjusted EPS. The company maintained its full-year revenue outlook while narrowing its adjusted EBITDA and EPS guidance ranges, driven by operational execution and strategic initiatives, including growth in acute and chronic therapy portfolios. Management highlighted investments in technology, cost controls, and share repurchases, affirming a focus on organic growth and potential strategic acquisitions for future expansion.
GUIDANCE: (OPCH) Option Care Health Expects Full Year 2026 Revenue Range $5.68B - $5.78B, Vs. FactSet Est of $5.71B
Option Care Health (OPCH) announced its financial guidance for the full year 2026, expecting revenue to be in the range of $5.68 billion to $5.78 billion. This guidance compares to FactSet's estimated revenue of $5.71 billion for the same period.
Ensign Group, Humana, Vitas Healthcare, Option Care Health report second-quarter earnings
The Ensign Group, Humana, Vitas Healthcare, and Option Care Health recently reported their second-quarter earnings. Ensign Group saw strong demand and anticipates a busy acquisition period, planning to expand into new states and having acquired 71 assets since 2025. Humana reaffirmed its commitment to increasing Medicare Advantage membership and will fund its acquisition of MaxHealth with the divestiture of its minority interest in Gentiva. Vitas Healthcare exceeded expectations with an 11.9% revenue increase and 9% rise in admissions over the prior year, while Option Care Health also surpassed internal expectations, reinforcing its confidence in long-term growth.
Option Care Health Releases Q2 2026 Financial Results
Option Care Health (OPCH) exceeded Wall Street expectations for the first half of 2026, reporting adjusted earnings per share of $0.45 and revenue of $1.44 billion. The company, a leading home infusion therapy provider, projects full-year 2026 adjusted EPS between $1.85 and $1.92, with revenue guidance of $5.67 billion, as it benefits from the shift towards home-based care. Analysts maintain a favorable outlook on the stock with a consensus of strong buy ratings.
Option Care Health, Inc. Q2 2026 Earnings Call Summary
Option Care Health, Inc. reported strong Q2 2026 results driven by high-single-digit organic growth in its acute portfolio and stabilization in its chronic inflammatory disease (CID) portfolio. The company utilized AI for operational effectiveness, expanded its ambulatory infusion clinic footprint, and repurchased $150 million in stock. Management expressed confidence in future growth by leveraging technology investments and commercial resources, while addressing potential impacts from biosimilars and white-bagging.
Option Care Health (NASDAQ:OPCH) Issues FY 2026 Earnings Guidance
Option Care Health (NASDAQ:OPCH) announced its FY 2026 earnings guidance, projecting EPS of $1.85–$1.92, which is higher than the consensus estimate of $1.80. The company also expects revenue between $5.7 billion and $5.8 billion, aligning with analyst forecasts. This announcement follows a strong quarterly performance where the company exceeded analyst expectations for both EPS and revenue.
Option Care: Q2 Earnings Snapshot
This article provides a second-quarter earnings snapshot for Option Care. No specific financial details or performance metrics are available in the provided content.
Option Care Health posts Q2 revenue $1.442B, GAAP net income $53.9M; adjusted diluted EPS $0.45
Option Care Health reported its second-quarter 2026 results, achieving $1.442 billion in net revenue and GAAP net income of $53.9 million. The company's adjusted diluted earnings per share stood at $0.45, with adjusted EBITDA reaching $117.5 million. Option Care Health also repurchased $150 million of stock and provided updated full-year and Q3 2026 guidance, emphasizing sequential revenue and Adjusted EBITDA growth.
Option Care Health earnings up next as census recovery takes center stage
Option Care Health (OPCH) is set to release its Q2 results, with investors keenly watching for signs of patient census recovery amidst challenges from biosimilar drugs and increased competition. Analysts anticipate 43 cents EPS on $1.42 billion revenue, showing sequential improvement but flat year-over-year growth. The company faces headwinds from biosimilar transitions, which have impacted its chronic inflammatory disease portfolio, but strong performance in acute care could offset these issues.
Option Care Health Number of Employees 2026 | Employee Count & Headcount Data
As of March 2026, Option Care Health (OPCH) has approximately 6,514 employees worldwide, marking a 1.1% growth since 2023 but a 0.8% year-over-year decline in 2026. The company is actively hiring with 933 job postings in 2026, despite a decrease in new postings per month. Its workforce is primarily concentrated in North America, with Finance and Operations being the largest functional group, and the average salary is $83,257.
Teca Partners LP Grows Position in Option Care Health, Inc. $OPCH
Teca Partners LP has increased its stake in Option Care Health, Inc. (NASDAQ:OPCH) by 20.6% in the first quarter, making it their third-largest holding. Institutional investors now own 98.05% of the company, which reported Q1 EPS of $0.40, beating estimates, and revenue of $1.35 billion. Analysts maintain a "Moderate Buy" rating with a consensus price target of $30.08, while company insiders have also significantly purchased shares.
Southpoint Capital Advisors LP Purchases 600,000 Shares of Option Care Health, Inc. $OPCH
Southpoint Capital Advisors LP increased its stake in Option Care Health by 20%, acquiring 600,000 additional shares to a total of 3.6 million shares, valuing their holding at approximately $96.9 million. Other institutional investors like Durable Capital Partners and Norges Bank also increased their positions in the company, bringing overall institutional ownership to 98.05%. Despite mixed analyst sentiment, with a "Moderate Buy" rating and an average price target of $30.08, insiders like Director Harry M. Jansen Kraemer, Jr. and CEO John Charles Rademacher have also recently purchased shares.
Option Care Health (OPCH) Reports Earnings Tomorrow: What To Expect
Option Care Health (OPCH) is set to announce its earnings results, with analysts expecting flat year-on-year revenue. The company missed revenue expectations last quarter, reporting $1.35 billion, but its full-year EBITDA guidance met expectations. Peers in the healthcare providers & services segment, like Tenet Healthcare and UnitedHealth, have reported varied results, with Tenet beating expectations and UnitedHealth reporting flat revenue.
